UnitedHealth stock price forecast: sideways bias expected as UnitedHealth stock loses 1.11% to $337.23

Traders Union
All News
Financial News
UnitedHealth Group slides 1.11% today

Highlights

UnitedHealth finalized its $3.3 billion acquisition of Amedisys after court approval, agreeing to divest 164 home health and hospice locations to satisfy regulators.
Stephen Hemsley returned as CEO amid ongoing Department of Justice investigations and heightened regulatory scrutiny of UnitedHealth operations.
UnitedHealth declared a quarterly dividend of $2.21 per share, payable December 16, 2025, and is currently working to stabilize its Medicare segment.

M&A integration and regulatory scrutiny reshape outlook amid leadership change

UnitedHealth has completed the $3.3 billion acquisition of Amedisys after court approval, agreeing to divest 164 home health and hospice locations as part of the deal. Leadership changes continued with Stephen Hemsley returning as CEO, while ongoing federal investigations and regulatory actions, including a Department of Justice probe, remain in focus. The company is also working on stabilizing its Medicare segment and has declared a quarterly dividend of $2.21 per share payable on December 16, 2025.

Divergent momentum as overbought signals conflict with mixed intraday action

Momentum signals on the daily chart are mixed. MACD and ADX both show neutral momentum, while RSI (57.38) is modestly bullish, and CCI and Stoch RSI flag strong overbought conditions. BBP indicates dominant buyer pressure intraday, yet the Awesome Oscillator supports a positive bias. Despite this, UNH opened with a minor gap down, trades mid-range for the session, and is off 1.11% from the previous close, highlighting moderate volatility and some pressure following the open. The breadth of signals and oscillators highlights a divergence between strong short-term buying and caution due to overbought readings, with intraday price action not fully confirming bullish momentum.

Sideways or pullback bias as weekly signals cap short-term rally potential

Looking ahead, the expected price range for the next five trading days is approximately $329–$345, within a typical volatility band relative to current levels. The probability of further short-term upside is very low (less than 20%), with the likelihood of a pullback or sideways movement more pronounced due to persistent weekly bearish signals from MA-50, MACD, and RSI. In the baseline scenario, UNH likely moves sideways within the $329–$345 corridor. A bullish case could see the price break above the $340–$345 resistance area, potentially toward $350 if momentum resumes, while a bearish scenario unfolds if support at $329–$330 fails, exposing the $324–$326 range and signaling further medium-term downside.

Viktoras Karapetjanc, senior analyst at Traders Union, sees UnitedHealth trading constructively in the short term despite persistent long-term resistance. He views the Amedisys acquisition and leadership changes as positive fundamental factors, but notes regulatory headwinds and overbought signals that temper the immediate outlook. The analyst expects the price to hold within the $329–$345 range, with limited short-term upside and a sideways to slightly bearish bias unless key resistance levels are broken. "Momentum is building, but confirmation above $345 is needed before a real breakout can develop here."

Previously it was reported that UnitedHealth Group is trading just below its 50-day moving average, with mixed technical signals as the RSI is positive but other momentum indicators suggest overbought conditions and neutral trend strength. The asset is expected to consolidate sideways between key support near $325 and resistance at $340, with a slight downside bias likely in the near term.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.